Avidity biosciences to present topline data from phase 1/2 fortitude™ trial of del-brax in people living with facioscapulohumeral muscular dystrophy at 32nd annual fshd society international research congress

-- fda alignment on accelerated and full approval pathways for delpacibart braxlosiran  (del-brax) in facioscapulohumeral muscular dystrophy (fshd) -- -- jeffrey m. statland, m.d.
RNA Ratings Summary
RNA Quant Ranking